Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Washington University in St. Louis · Alvin J. Siteman Cancer Center · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
772
total citations
- FWCI
- 29.87
- Percentile
- 100%
- References
- 34
Citations per year
Authors
21- TMTimothy M. Nywening
Washington University in St. Louis, Alvin J. Siteman Cancer Center
- AWAndrea Wang‐Gillam
Alvin J. Siteman Cancer Center, Washington University in St. Louis
- DEDominic E. Sanford
Washington University in St. Louis
- BABrian A. Belt
University of Rochester Medical Center
- RZRoheena Z. Panni
Washington University in St. Louis
Topics & keywords
Topics
Keywords
- FOLFIRINOX
- Open label
- Medicine
- Pancreatic cancer
- Oncology
- Internal medicine
- Maximum tolerated dose
- Gemcitabine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.